{
    "organizations": [],
    "uuid": "7e3e09dd54de330d09653d7c1b51c5cb801de478",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fate-therapeutics-announces-first/brief-fate-therapeutics-announces-first-subject-treated-with-fate-nk100-in-dimension-study-for-advanced-solid-tumors-idUSFWN1QA0KK",
    "ord_in_thread": 0,
    "title": "BRIEF-Fate Therapeutics Announces First Subject Treated With Fate-NK100 In Dimension Study For Advanced Solid Tumors",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Fate Therapeutics Inc:\n* FATE THERAPEUTICS ANNOUNCES FIRST SUBJECT TREATED WITH FATE-NK100 IN DIMENSION STUDY FOR ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T21:23:00.000+02:00",
    "crawled": "2018-02-21T21:23:23.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "fate",
        "therapeutic",
        "inc",
        "fate",
        "therapeutic",
        "announces",
        "first",
        "subject",
        "treated",
        "dimension",
        "study",
        "advanced",
        "solid",
        "tumor",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}